Skip to main content
An official website of the United States government

Denosumab

Placeholder slot
 (deh-noh-SOO-mab)

This page contains brief information about denosumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Prolia
Xgeva
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Denosumab is approved to treat:

Denosumab is approved to prevent:

  • broken bones and other bone problems caused by multiple myeloma or by solid tumors that have spread to bone. This use is approved for the Xgeva brand of denosumab

Denosumab is also approved to increase bone mass in adults who have a high risk of breaking bones. It is used in the following types of cancer:

Denosumab is also being studied in the treatment of other conditions and types of cancer.

More About Denosumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Denosumab - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Jaw Problems Linked to Bone-Modifying Drugs Not as Rare as Once Thought

Targeted Therapy to Treat Cancer

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Denosumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email